Novel, broad-spectrum anticonvulsants containing a sulfamide group: Pharmacological properties of (S)- N -[(6-chloro-2,3-dihydrobenzo[1,4]dioxin-2- yl)methyl]sulfamide (JNJ-26489112)

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9019-9030

  McComsey, David F ^a   Smith Swintosky, Virginia L ^a   Parker, Michael H ^a   Brenneman, Douglas E ^a   Malatynska, Ewa ^a   White, H Steve ^b   Klein, Brian D ^b   Wilcox, Karen S ^b   Milewski, Michael E ^a   Herb, Mark ^a   Finley, Michael F A ^a   Liu, Yi ^a   Lubin, Mary Lou ^a   Qin, Ning ^a   Reitz, Allen B ^a   Maryanoff, Bruce E ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; BICUCULLINE; CALCIUM CHANNEL N TYPE; CARBAMAZEPINE; CARBONATE DEHYDRATASE II; ETHOSUXIMIDE; ETIRACETAM; JNJ 26489112; LAMOTRIGINE; N (HROMAN 2 YLMETHYL)SULFAMIDE; N [(2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL] N',N' DIMETHYLSULFAMIDE; N [(2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL]SULFAMIDE; N [(3,4 DIHYDRO 2H BENZO[B][1,4]DIOXEPIN 3 YL)METHYL]SULFAMIDE; N [(6 CHLORO 2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL]SULFAMIDE; N [(6 FLUORO 2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL]SULFAMIDE; N [(6,7 DICHLORO 2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL]SULFAMIDE; N [(7 METHYL 2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL]SULFAMIDE; N [2 (2,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)ETHYL]SULFAMIDE; N [92,3 DIHYDROBENZO[1,4]DIOXIN 2 YL)METHYL] N METHYLSULFAMIDE; PENTETRAZOLE; PHENYTOIN; PICROTOXIN; POTASSIUM CHANNEL; SULFAMIDE DERIVATIVE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VOLTAGE GATED SODIUM CHANNEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTICONVULSANT THERAPY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ELECTRIC SHOCK; ENZYME INHIBITION; EPILEPSY; MALE; MAXIMAL ELECTROSHOCK SEIZURE; MOUSE; NEUROTOXICITY; NONHUMAN; RAT; SEIZURE; SEIZURE THRESHOLD;

ABSORPTION; AMIDES; ANIMALS; ANTICONVULSANTS; DIOXANES; DOGS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE; EPILEPSY; FEMALE; HUMANS; MALE; MICE; RATS; SULFONAMIDES;

EID: 84889262867     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400894u     Document Type: Article

References (60)

1. Media Center, Epilepsy Fact Sheet; World Health Organization: Geneva, 2013; http://www.who.int/mediacentre/factsheets/fs999/en/index.html (accessed 2 June 2013).
2. White, H. S.; Smith, M. D.; Wilcox, K. S. Mechanisms of action of antiepileptic drugs Int. Rev. Neurobiol. 2007, 81, 85-110
3. Calabresi, P.; Galletti, F.; Rossi, C.; Sarchielli, P.; Cupini, L. M. Antiepileptic drugs in migraine: from clinical aspects to cellular mechanisms Trends Pharmacol. Sci. 2007, 28, 188-195 (Pubitemid 46505168)
4. Landmark, C. J. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy CNS Drugs 2008, 22, 27-47
5. Ettinger, A. B.; Argoff, C. E. Use of antiepileptic drugs for nonepileptic conditions: psychiatric disorders and chronic pain Neurotherapeutics 2007, 4, 75-83 (Pubitemid 46110806)
6. Zaremba, P. D.; Bialek, M.; Blaszczyk, B.; Cioczek, P.; Czuczwar, S. J. Non-epilepsy uses of antiepileptic drugs Pharmacol. Rep. 2006, 58, 1-12
7. Maryanoff, B. E. Pharmaceutical "gold" from neurostabilizing agents: topiramate and successor molecules J. Med. Chem. 2009, 52, 3431-3440
8. Maryanoff, B. E.; Nortey, S. O.; Gardocki, J. F.; Shank, R. P.; Dodgson, S. P. Anticonvulsant O -alkyl sulfamates. 2,3:4,5-Bis- O -(1-methylethylidene)- β- d -fructopyranose sulfamate and related compounds J. Med. Chem. 1987, 30, 880-887
9. Shank, R. P.; Gardocki, J. F.; Vaught, J. L.; Davis, C. B.; Schupsky, J. J.; Raffa, R. B.; Dodgson, S. J.; Nortey, S. O.; Maryanoff, B. E. Topiramate: preclinical evaluation of a structurally novel anticonvulsant Epilepsia 1994, 35, 450-460 (Pubitemid 24138837)
10. Maryanoff, B. E.; Margul, B. L. Topiramate Drugs Future 1989, 14, 342-344 (Pubitemid 19127277)
11. Maryanoff, B. E. Sugar sulfamates for seizure control: discovery and development of topiramate, a structurally unique antiepileptic drug Curr. Top. Med. Chem. 2009, 9, 1048-1061
12. TOPAMAX (topiramate) attained peak, annual global sales of $2.7 billion in 2008, as indicated in the 2008 Johnson & Johnson Annual Report, p 23 (http://www.jnj.com/wps/wcm/connect/a9a1fd804d5592ab9b16db1bc89e29c7/2008- Annual-Report.pdf?MOD=AJPERES).
13. Shank, R. P.; Maryanoff, B. E. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate CNS Neurosci. Ther. 2008, 14, 120-142 (Pubitemid 351713317)
14. Maryanoff, B. E.; Costanzo, M. J.; Nortey, S. O.; Greco, M. N.; Shank, R. P.; Schupsky, J. J.; Ortegon, M. E.; Vaught, J. L. Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives J. Med. Chem. 1998, 41, 1315-1343 (Pubitemid 28208186)
15. Parker, M. H.; Smith-Swintosky, V. L.; McComsey, D. F.; Huang, Y.; Brenneman, D.; Klein, B.; Malatynska, E.; Plata-Salaman, C.; White, H. S.; Milewski, M. E.; Herb, M.; Finley, M. F. A.; Liu, Y.; Lubin, M. L.; Qin, N.; Iannucci, R.; Leclercq, L.; Cuyckens, F.; Reitz, A. B.; Maryanoff, B. E. Novel broad-spectrum anticonvulsants containing a sulfamide group: advancement of N -((benzo[ b ]thien-3-yl)methyl)sulfamide (JNJ-26990990) into human clinical studies J. Med. Chem. 2009, 52, 7528-7536
16. Gavernet, L.; Cabrera, M. J. D.; Bruno-Blanch, L. E.; Estiu, G. L. 3D-QSAR design of novel antiepileptic sulfamides Bioorg. Med. Chem. 2007, 15, 1556-1567 (Pubitemid 46038118)
17. Gavernet, L.; Barrios, I. A.; Cravero, M. S.; Bruno-Blanch, L. E. Design, synthesis, and anticonvulsant activity of some sulfamides Bioorg. Med. Chem. 2007, 15, 5604-5614 (Pubitemid 46962986)
18. Gavernet, L.; Elvira, J. E.; Samaja, G. A.; Pastore, V.; Sella Cravero, M.; Enrique, A.; Estiu, G.; Bruno-Blanch, L. E. Synthesis and anticonvulsant activity of amino acid-derived sulfamides J. Med. Chem. 2008, 52, 1592-1601
19. For a review on biologically active sulfamides, see: Winum, J.-V.; Scozzafava, A.; Montero, J.-L.; Supuran, C. T. The sulfamide motif in the design of enzyme inhibitors Expert Opin. Ther. Pat. 2006, 16, 27-47 (Pubitemid 43056401)
20. Maryanoff, B. E.; McComsey, D. F.; Costanzo, M. J.; Hochman, C.; Smith-Swintosky, V.; Shank, R. P. Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform J. Med. Chem. 2005, 48, 1941-1947 (Pubitemid 40396324)
21. Klinger, A. L.; McComsey, D. F.; Smith-Swintosky, V.; Shank, R. P.; Maryanoff, B. E. Inhibition of carbonic anhydrase-II by sulfamate and sulfamide groups: an investigation involving direct thermodynamic binding measurements J. Med. Chem. 2006, 49, 3496-3500 (Pubitemid 43902456)
22. Shank, R. P.; McComsey, D. F.; Smith-Swintosky, V. L; Maryanoff, B. E. Examination of two independent kinetic assays for determining the inhibition of carbonic anhydrases I and II: structure-activity comparison of sulfamates and sulfamides Chem. Biol. Drug Des. 2006, 68, 113-119 (Pubitemid 44454429)
23. Shank, R. P.; Smith-Swintosky, V. L; Maryanoff, B. E. Carbonic anhydrase inhibition. Insight into the characteristics of zonisamide, topiramate, and the sulfamide cognate of topiramate J. Enzym. Inhib. Med. Chem. 2008, 23, 271-276 (Pubitemid 351404848)
24. Maryanoff, B. E.; McComsey, D. F.; Lee, J.; Smith-Swintosky, V. L.; Wang, Y.; Minor, L. K.; Todd, M. J. Carbonic anhydrase-II inhibition. What are the true enzyme inhibitory properties of the sulfamide cognate of topiramate? J. Med. Chem. 2008, 51, 2518-2521 (Pubitemid 351628513)
25. Nelson, W. L.; Powell, M. L.; Dyer, D. C. Absolute configuration of glycerol derivatives. 7. Enantiomers of 2-[[[2-(2,6-dimethoxyphenoxy)ethyl] amino]methyl]-1,4-benzodioxane (WB-4101), a potent competitive α-adrenergic antagonist J. Med. Chem. 1979, 22, 1125-1127 (Pubitemid 10226810)
26. Delgado, A.; Leclerc, G.; Lobato, M. C.; Mauleon, D. Short and enantioselective synthesis of (R)- and (S)-2-hydroxymethyl-1,4-benzodioxane Tetrehedron Lett. 1988, 29, 3671-3674
27. 1A partial agonists with potential as atypical antipsychotic agents J. Med. Chem. 1999, 42, 3342-3355 (Pubitemid 29409723)
28. Swinyard, E. A.; Brown, W. C.; Goodman, L. S. Comparative assays of antiepileptic drugs in mice and rats J. Pharmacol. Exp. Ther. 1952, 106, 319-330
29. Swinyard, E. A. Laboratory evaluation of antiepileptic drugs: review of laboratory methods Epilepsia 1969, 10, 107-119
30. Irwin, S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse Psychopharmacologia 1968, 13, 222-257
31. Cerep, an independent contract laboratory, can be contacted at www.cerep.com.
32. 50 value for acetazolamide, a reference standard, was <10 nM.
33. Shingles, R.; Moroney, J. V. Measurement of carbonic anhydrase activity using a sensitive fluorometric assay Anal. Biochem. 1997, 252, 190-197 (Pubitemid 27408710)
34. White, H. S.; Woodhead, J. H.; Wilcox, K. S.; Stables, J. P.; Kupferberg, H. J.; Wolf, H. H. General principles: discovery and preclinical development of antiepileptic drugs. In Antiepileptic Drugs, 5th ed.; Levy, R. H.; Mattson, R. H.; Meldrum, B. S.; Perruca, E., Eds.; Lippincott, Williams and Wilkins: Philadelphia, PA, 2002; pp 36-48.
35. Lothman, E. W.; Salerno, R. A.; Perlin, J. B.; Kaiser, D. L. Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats Epilepsy Res. 1988, 2, 367-379
36. Lothman, E. W.; Perlin, J. B.; Salerno, R. A. Response properties of rapidly recurring hippocampal seizures in rats Epilepsy Res. 1988, 2, 356-366
37. Soderpalm, B. Anticonvulsants: aspects of their mechanisms of action Eur. J. Pain 2002, 6, 3-9
38. Liu, G.; Yarov-Yarovoy, V.; Nobbs, M.; Clare, J. J.; Scheuer, T.; Catterall, W. A. Differential interactions of lamotrigine and related drugs with transmembrane segment IVS6 of voltage-gated sodium channels Neuropharmacology 2003, 44, 413-422 (Pubitemid 36246496)
39. White, H. S.; Smith, M. D.; Wilcox, K. S. Mechanisms of action of antiepileptic drugs Intl. Rev. Neurobiol. 2007, 81, 85-110
40. Rogawski, M. A. Diverse mechanisms of antiepileptic drugs in the development pipeline Epilepsy Res. 2006, 69, 273-294 (Pubitemid 44209049)
41. Lombardo, A. J.; Kuzniecky, R.; Powers, R. E.; Brown, G. B. Altered brain sodium channel transcript in human epilepsy Mol. Brain Res. 1996, 35, 84-90 (Pubitemid 26036735)
42. Rogawski, M. A.; Loscher, W. The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions Nature Med. 2004, 10, 685-692 (Pubitemid 38937632)
43. Rogawski, M. A.; Loscher, W. The neurobiology of antiepileptic drugs Nature Rev. Neurosci. 2004, 5, 553-564 (Pubitemid 38868551)
44. Wang, H.-S.; Pan, Z.; Shi, W.; Brown, B. S.; Wymore, R. S.; Cohen, I. S.; Dixon, J. E.; McKinnon, D. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel Science 1998, 282, 1890-1893 (Pubitemid 28555268)
45. Gribkoff, V. K. The therapeutic potential of neuronal KCNQ channel modulators Expert Opin. Ther. Targets 2003, 7, 737-748 (Pubitemid 37541260)
46. Hertz, E.; Yu, A. C. H.; Hertz, L.; Juurlink, B. H. J.; Schousboe, A. Preparation of primary cultures of mouse cortical neurons. In A Dissection and Tissue Culture Manual of the Nervous System; Shahar, A.; De Vellis, J.; Vernadakis, A.; Haber, B., Eds.; Alan R. Liss, Inc.: New York, 1989, pp 183-186.
47. Skeen, G. A.; White, H. S.; Twyman, R. E. The dihydropyridine nitrendipine reduces N -methyl- d -aspartate (NMDA)-evoked currents of rodent cortical neurons through a direct interaction with the NMDA receptor-associated ion channel J. Pharmacol. Exp. Ther. 1994, 271, 30-38 (Pubitemid 24333110)
48. Hamill, O. P.; Marty, A.; Neher, E.; Sakmann, B.; Sigworth, F. J. Improved patch-clamp technique for high-resolution current recording from cells and cell-free membrane patches Pfluger's Archiv.: Eur. J. Physiol. 1981, 391, 85-100 (Pubitemid 11012976)
49. Brown, H. C.; Kim, K. W.; Srebnik, M.; Singaram, B. Organoboranes for synthesis. 7. An improved general synthesis of primary amines from alkenes via hydroboration-organoborane chemistry Tetrahedron 1987, 43, 4071-4078
50. White, H. S.; Wolf, H. H.; Woodhead, J. H.; Kupferberg, H. J. The National Institutes of Health Anticonvulsant Drug Development Program: Screening for Efficacy Adv. Neurol. 1998, 76, 29-39
51. Orloff, M. J.; Williams, H. L.; Pfeiffer, C. C. Timed intravenous infusion of metrazol and strychnine for testing anticonvulsant drugs Proc. Soc. Exp. Biol. Med. 1949, 70, 254-257
52. White, H. S.; Patel, S.; Meldrum, B. S. Anticonvulsant profile of MDL 27,266: an orally active, broad-spectrum anticonvulsant agent Epilepsy Res. 1992, 12, 217-226
53. Lothman, E. W.; Salerno, R. A.; Perlin, J. B.; Kaiser, D. L. Screening and characterization of antiepileptic drugs with rapidly recurring hippocampal seizures in rats Epilepsia 1988, 2, 367-379
54. Köhling, R. Voltage-gated sodium channels in epilepsy Epilepsia 2002, 43, 1278-1295 (Pubitemid 35370020)
55. Liu, Y.; Qin, N.; Reitz, T.; Wang, Y.; Flores, C. M. Inhibition of the rat brain sodium channel Nav1.2 after prolonged exposure to gabapentin Epilepsy Res. 2006, 70, 263-268 (Pubitemid 44209224)
56. Benjamin, E. R.; Pruthi, F.; Olanrewaju, S.; Ilyin, V. I.; Crumley, G.; Kutlina, E.; Valenzano, K. J.; Woodward, R. M. State-dependent compound inhibition of Nav1.2 sodium channels using the FLIPR Vm dye: on-target and off-target effects of diverse pharmacological agents J. Biomol. Screening 2006, 11, 29-39 (Pubitemid 43255779)
57. Lukyanetz, E. A.; Shkryl, V. M.; Kostyuk, P. G. Selective blockade of N-type calcium channels by levetiracetam Epilepsia 2002, 43, 9-18 (Pubitemid 34215447)
58. Kuzmiski, J. B.; Barr, W.; Zamponi, G. W.; Mac Vicar, B. A. Topiramate inhibits the initiation of plateau potentials in CA1 neurons by depressing R-type calcium channels Epilepsia 2005, 46, 481-489 (Pubitemid 40470669)
59. Dunham, M. S.; Miya, T. A. A note on a simple apparatus for detecting neurological deficit in rats and mice J. Am. Pharm. Assoc. Sci. Ed. 1957, 46, 208-209
60. Studies were conducted by NeuroAdjuvants.